- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.03. | How discoverable, comparable and explorable is your data? | ||
| 28.03. | FDA approves first-of-its-kind RNA drug for hemophilia | ||
| 28.03. | Bluebird gets rival takeout offer from Ayrmid | ||
| 28.03. | FDA broadens use of Novartis' radiopharma drug Pluvicto | ||
| 28.03. | 'Everything is word of mouth': HHS employees face uncertainty in looming Trump layoffs | ||
| 28.03. | Lilly hits same Alzheimer's roadblock in Europe as Eisai, Biogen | ||
| 28.03. | Novo gains Lexicon obesity drug; CRISPR COO to step down | ||
| 27.03. | Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy | ||
| 27.03. | Alcon buys majority stake in IPO-seeking cell therapy startup Aurion | ||
| 27.03. | HHS to cut 10,000 staff in major restructuring under RFK Jr. | ||
| 26.03. | First Prader-Willi drug to reduce hunger approved by FDA | ||
| 26.03. | FDA approves first-of-its-kind antibiotic from GSK | ||
| 26.03. | Makary confirmed by Senate as FDA commissioner | ||
| 26.03. | Bayer gains cancer drug from China's Puhe; Axsome gets mixed ADHD data | ||
| 26.03. | Wave to seek approval of Duchenne drug after mid-stage study data | ||
| 26.03. | Epicrispr banks $68M to test epigenetic editing on rare muscle disease | ||
| 25.03. | Merck bets $200M on a new type of heart pill | ||
| 25.03. | Character Biosciences raises $93M with an eye on vision loss drugs | ||
| 24.03. | Verve gets FDA green light to expand base editing trial into US | ||
| 24.03. | 23andMe files for bankruptcy as CEO Anne Wojcicki resigns | ||
| 24.03. | Novo adds to obesity drug pipeline via $200M deal with China-based biotech | ||
| 24.03. | Biogen plots new global headquarters in Kendall Square | ||
| 24.03. | Tempero Bio gets $70M to advance substance abuse treatment | ||
| 24.03. | Accelerate oncology drug development: A data-driven approach to clinical decisions | ||
| 24.03. | Leveraging clinical and financial data sets to guide investment strategies in 2025's biopharma market |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
